drugset / Trial / NCT06875973
Pelacarsen Roll-over Extension Program
NaSingle-groupOpen-labelTreatment
Summary
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
Timeline
- Start
- 2025-05-19
- Primary completion
- 2030-12-08
- Completion
- 2030-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pelacarsen | Antisense oligonucleotide | 80 mg | Subcutaneous |